Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 179

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 179
---
 prevent third parties
from seeking to register, acquire, or otherwise obtain trademarks, copyrights or domain names that are similar to, infringe upon or diminish
the value of its trademarks, copyrights, and its other proprietary rights. Third parties may obtain or misappropriate certain of its data
through website scraping, robots, or other means to launch copycat sites, aggregate its data for their internal use, or to feature or
provide its data through their respective websites, and/or launch businesses monetizing this data. While DiamiR routinely employs technological
and legal measures in an attempt to divert, halt, or mitigate such operations, it may not always be able to detect or halt the underlying
activities as technologies used to accomplish these operations continue to rapidly evolve.

If the protection of its proprietary rights and data is inadequate
to prevent unauthorized use or misappropriation by third parties, the value of its brand and other intangible assets may be diminished
and its competitors may be able to more effectively mimic its technologies, offerings, or features or methods of operations. Even if DiamiR
does detect violations or misappropriations and decide to enforce its rights, litigation that may be necessary to enforce its rights may
not be pursued by DiamiR, as it may be time-consuming and expensive, and divert its management’s attention. Additionally, a court
of a competent jurisdiction may determine that certain of DiamiR’s intellectual property rights are unenforceable. If DiamiR fails
to protect its intellectual property and data in a cost-effective and meaningful manner, its competitive standing could be harmed and
the brand, reputation, business, results of operations, and financial condition could be materially adversely affected.

Intellectual Property infringement claims by other companies could result in costly disputes and could limit DiamiR’s ability to sell its products.

Litigation over intellectual property is prevalent in the molecular
diagnostics industry. As the market for molecular diagnostics continues to grow and the number of participants in the market increases,
DiamiR may increasingly be subject to patent infringement claims. While DiamiR may attempt to obtain licenses to such patents, DiamiR
may be unable to do so on favorable terms, or at all. Additionally, if its products are found to infringe third-party patents, DiamiR
may be required to pay damages and/or lose the ability to sell certain products, causing its revenues to decrease or causing damage to
DiamiR’s reputation in the industry also leading to a material adverse effect on DiamiR’s business.